Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for refractory autoimmune blistering diseases
jRCTs031180220Completed
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of rituximab in pemphigus vulgaris (PV), paraneoplastic pemphigus (PNP) and Bullous Pemphigoid (BP). Primary endpoint: Reduction of immunosuppressive agent and steroid dose. Started May 2014; status: completed.
02
Drugs
rituximab
03
Conditions
pemphigus vulgaris (PV)paraneoplastic pemphigus (PNP)Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on jRCTs031180220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180220.